Nomura Y, Schmidt-Glenewinkel T, Giacobini E, Ortiz J
J Neurosci Res. 1983;9(3):279-89. doi: 10.1002/jnr.490090305.
Cadaverine and pipecolic acid metabolism was investigated in vitro in several organs of the mouse by measuring 14CO2 formation from labeled precursors. The liver showed the highest formation of 14CO2 from [1,5-14C]-cadaverine, whereas brain demonstrated a much lower formation. Anaerobiosis or inhibition of monoamineoxidase (MAO) activity significantly reduced 14CO2 formation in every organ, but inhibition of diamine oxidase (DAO) activity had no effect in brain and kidney. Piperidine was formed from cadaverine in vitro only in the large intestine and its content. This formation is probably of bacterial origin. Under a variety of experimental conditions we were unable to demonstrate any formation of piperidine in brain from cadaverine. Biosynthesis in vitro of [3H]-piperidine from D,L-[3H]-pipecolic acid was very low in brain and kidney. With the exception of brain and kidney, no other organs showed any formation of [3H]-piperidine. Neither MAO nor DAO inhibition influenced [3H]-piperidine formation in the large intestine with its content. Following 1 hr incubation at 37 degrees C under aerobic conditions, the levels of [14C]-pipecolic acid and [3H]-piperidine recovered from mouse brain homogenate did not indicate any significant degradation of these two substances. Our results suggest that under in vitro conditions, cadaverine is not a precursor of piperidine in brain, liver, heart, and kidney and that only very low levels of piperidine can be formed from pipecolic acid in brain. Outside the brain, formation of piperidine from pipecolic acid is detectable only in kidney and in the content of the large intestine. The latter is probably of bacterial origin. Our results do not support previous findings from other authors on an endogenous origin of piperidine in brain from cadaverine and pipecolic acid, and they suggest that a) cadaverine is not a precursor of piperidine in brain, b) the conversion of pipecolic acid into piperidine in the brain does not constitute a major metabolic pathway, and c) the main source of piperidine in the CNS may be of nonneural origin.
通过测量标记前体生成的(^{14}CO_2),在体外研究了小鼠多个器官中尸胺和哌啶酸的代谢情况。肝脏从([1,5 - ^{14}C]) - 尸胺生成(^{14}CO_2)的量最高,而脑生成的量则低得多。无氧条件或单胺氧化酶(MAO)活性的抑制显著降低了每个器官中(^{14}CO_2)的生成,但二胺氧化酶(DAO)活性的抑制对脑和肾没有影响。体外仅在大肠及其内容物中由尸胺生成哌啶。这种生成可能源于细菌。在各种实验条件下,我们均未能证明脑内由尸胺生成哌啶。脑和肾中由D,L - ([^{3}H]) - 哌啶酸体外生物合成([^{3}H]) - 哌啶的量非常低。除脑和肾外,没有其他器官显示有([^{3}H]) - 哌啶的生成。MAO和DAO的抑制均不影响大肠及其内容物中([^{3}H]) - 哌啶的生成。在有氧条件下于(37^{\circ}C)孵育1小时后,从小鼠脑匀浆中回收的([^{14}C]) - 哌啶酸和([^{3}H]) - 哌啶的水平未显示这两种物质有任何显著降解。我们的结果表明,在体外条件下,尸胺不是脑、肝、心和肾中哌啶的前体,并且脑中由哌啶酸生成的哌啶水平极低。在脑外,仅在肾和大肠内容物中可检测到由哌啶酸生成哌啶。后者可能源于细菌。我们的结果不支持其他作者先前关于脑内哌啶内源性源于尸胺和哌啶酸的研究结果,并且表明:a)尸胺不是脑中哌啶的前体;b)脑中哌啶酸向哌啶的转化不构成主要代谢途径;c)中枢神经系统中哌啶的主要来源可能是非神经源性的。